Pharmaceutical company works to unlock potential of psychedelic drugs for stroke recovery

0

Algernon Pharmaceuticals CEO Christopher J. Moreau and Dr. David Nutt, the company’s stroke research consultant, discuss Algernon’s upcoming Phase 1 study of DMT for stroke.

Streetwise Live! Released on July 8, 2021, focused on Algernon Pharmaceuticals Inc. (AGN: CSE; AGNPF: OTCQB; AGW: FSE), the only public company currently researching psychedelics to help repair the brain after stroke. Guests, Algernon CEO Christopher Moreau, and his stroke research consultant, Dr. David Nutt, discussed biopharma’s clinical stroke program.

Host Cyndi Edwards kicked off the show by asking Algernon CEO Christopher Moreau why he thinks the use of the psychedelic drug dimethyltryptamine (DMT) might show positive results in stroke patients when many drugs used in the past have failed. Moreau cited positive preclinical results for DMT.

On the one hand, in vitro experiments, in which brain cells have been exposed to DMT and various other psychedelics for different periods of time, result in an increased density of complexity in neurons. Additionally, an animal study has shown that a sub-psychedelic dose of DMT can treat depression. In a third study, a stroke was recreated in rats, which were then treated with DMT. After 30 days, the rats exhibited a recovery of motor function and a reduced area of ​​dead cells.

“It’s all a matter of science,” added Moreau. “Animal data gives us hope.”

Dr David Nutt, who consults Algernon on stroke research, added that Algernon’s approach differs from that of any other company researching potential stroke drugs to date. Instead of trying to reduce the damage caused by the lack of oxygen to the brain that occurs during a stroke, Algernon seeks to regrow the brain and speed recovery after stroke.

Like psilocybin and LSD, DMT stimulates serotonin 5-HT2A receptors in humans, which are widely distributed in the brain and are important for cellular and neuronal activity.

Algernon’s approach “is a fundamentally different approach conceptually,” Nutt said. It’s seeing “if we can do [stroke recovery] bigger, stronger and faster through this mechanism by stimulating these HT2A receptors. “

How optimistic is Nutt, on a scale of 1 to 10, that DMT will help stroke patients, Edwards asked. He’s about 3 right now, he said, but with positive data from human trials he’s hoping to increase to 5 or 6.

“We have to be realistic, but this is new,” added Nutt. “It’s a different way. It makes the brain grow, not just stop the brain from dying.”

Edwards asked Moreau to discuss Algernon’s clinical plan for DMT in stroke patients. A Phase 1 safety and dosage study is scheduled for October at Hammersmith Medicines Research in England, near the Nutt location, noted Moreau. The aim of this study is to determine the ideal sub-psychedelic dose to administer and for how long.

In the phase 2 study, which could start as early as Q1 / 22 if all goes as planned, Algernon will test DMT in patients with stroke. First, Algernon will administer DMT to stroke patients who are in rehab, which typically begins 24 to 48 hours after the event. Next, the biopharmacy will target patients who have or have recently had a stroke to determine how soon they can receive DMT after stroke and whether the effects will be the same as those of treatment during the rehabilitation phase.

Was DMT approved for stroke, Edwards asked Nutt, would people’s fear of psychedelics hinder absorption of the drug? Nutt replied that there is a lot of misinformation out there about DMT and other psychedelics and that the best way to counteract this is with positive data. He added that doctors would likely be willing to use DMT given the scarcity of current stroke treatments.

In his final comments, Moreau said Algernon is a drug reuse company, looking to reuse DMT. While the drug has not been approved, it has been used for purposes other than treating stroke patients.

“We move forward [DMT]”, he said.” We are going to do it with efficiency and speed of capital. And with good quality research, hope it will make some difference in people’s lives. This is what we are trying to do. “

[NLINSERT]

Disclosure of Streetwise Reports:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or the members of her household hold securities in the following companies mentioned in the article: None. She or the members of her household are remunerated by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are sponsors of the Streetwise Reports bulletin board: Algernon Pharmaceuticals. Click here for important information on referral fees. As of the date of this article, a subsidiary of Streetwise Reports has an advisory relationship with Algernon Pharmaceuticals. Click here for more information.

3) Comments and opinions expressed are those of specific experts and not of Streetwise Reports or its managers. The information provided above is for informational purposes only and does not constitute a recommendation to buy or sell securities.
4) The article does not constitute investment advice. Each reader is encouraged to consult their financial professional and any action taken by a reader following the information presented here is at their own responsibility. By opening this page, each reader accepts and accepts the terms of use and the entire Streetwise Reports disclaimer. This article is not an investment solicitation. Streetwise Reports does not give general or specific investment advice, and information on Streetwise Reports should not be taken as a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the activities, products, services or titles of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or their family members, as well as those interviewed for articles and interviews on the Site, may have a long or short position on the titles mentioned. Directors, officers, employees or their immediate family members are prohibited from making any purchases and / or sales of these securities on the open market or otherwise from the time of the decision to publish an article up to three days. working days after publication of the article. The foregoing ban does not apply to articles which, in essence, only repeat previously published company releases. As of the date of this article, officers and / or employees of Streetwise Reports LLC (including their household members) own securities of Algernon Pharmaceuticals, a company mentioned in this article.
6) This article does not constitute medical advice. Streetwise Reports officers, employees and contributors are not licensed healthcare professionals. Readers should always contact their healthcare professionals for medical advice.

See the video below:

[NLINSERT]

Streetwise Live! Disclosures:

  1. This dissemination does not constitute investment advice. Each viewer is encouraged to consult their financial professional and any action taken by a viewer as a result of the information presented here is their own responsibility. This issue is not a solicitation of investment. In the street Live! does not give general or specific investment advice and the information should not be taken as a recommendation to buy or sell any security. In the street Live! does not endorse or recommend the business, products, services or titles of any business mentioned herein.
  2. Statements and opinions expressed are the opinions of the presenters and not of Streetwise Live! or his officers. Presenters are fully responsible for the validity of statements. The presenter was not paid by Streetwise Live! for this show. In the street Live! requires presenters to disclose any economic involvement or relationship with the companies they write about. In the street Live! relies on the authors to accurately provide this information and Streetwise Live! has no way of verifying its accuracy.
  3. The following companies discussed in this show paid a fee of $ 10,000 to participate: Algernon Pharmaceuticals Inc.
  4. Every now and then, Streetwise Live! and its directors, officers, employees or members of their families, as well as those interviewed for broadcasts and interviews on the site, may have a long or short position on the titles mentioned. As of the date of this broadcast, the officers and / or employees of Streetwise Live! (including members of their household) own securities of the following companies discussed in this program: Algernon Pharmaceuticals Inc. Algernon Pharmaceuticals Inc. has an advisory relationship with a subsidiary of Streetwise Live! (description available at https://www.streetwisereports.com/disclaimer/html#consulting). Algernon Pharmaceuticals Inc. is a display sponsor of Streetwise Reports, a subsidiary of Streetwise Live! (description available at https://www.streetwisereports.com/disclaimer/).
  5. Christopher Moreau – CEO owns securities of the company.
  6. Disclosures for: Dr. David Nutt – Professor, Imperial College of London. I, or members of my immediate family or relatives, own securities of the following companies featured on the show: None. I personally, or my immediate household or family members, are paid by the following companies mentioned on the show: Algernon Pharmaceuticals Inc. My company has a financial relationship with the following companies mentioned on the show: Consultant.
  7. Disclosures for: Cyndi Edwards, host. I, or members of my family or immediate household, own securities in the following companies mentioned in the program: Nothing. My company has a financial relationship with the following companies featured on the show: My husband’s company has a contract with Algernon to do public relations, but I don’t personally have one.



Source link

Leave A Reply

Your email address will not be published.